NCT03286829 - Study to Investigate the Pharmacokinetic Profile | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

February 6, 2018

Study Completion Date

February 6, 2018

Conditions

Healthy Male Subjects

Interventions

DRUG

"Tesomet High dose in fasted condition"

To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

DRUG

"Tesomet Low dose in fasted condition"

To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

DRUG

Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.

To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

DRUG

"Tesomet High dose in fed condition"

To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.

Trial Locations (1)

14050

Early Phase Clinical Unit;Klinikum Westend, Haus 31, Berlin